Abstract 1673P
Background
There is still a profound lack of efficient therapeutic strategies against pancreatic or other periampullary adenocarcinoma. Surgery is seldom possible, leaving palliative chemotherapy the only option for most patients. Chemotherapy treatment is however often accompanied by serious side-effects, and the identification of biomarkers for early prediction of disease and treatment-associated symptoms could help alleviate patient suffering. This study investigated the dynamic interrelationship between immune-related serum proteins, routine biomarkers and health-related quality of life (HRQoL) factors during chemotherapy treatment of patients enrolled in the prospective, observational study Chemotherapy, Host response And Molecular dynamics in Periampullary cancer (CHAMP).
Methods
Proximity extension assay was applied to analyse 92 immune-associated proteins in longitudinal serum samples from 75 patients, 18 being treated with adjuvant and 57 with palliative intent. HRQoL data were available from all patients at baseline (BL), from 41 patients at three months, and from 23 patients at six months.
Results
Levels of 8 proteins; CCL23, CD4, CD28, DCN, Gal-1, GZMB, GZMH and MMP7 were strongly correlated (Spearman´s Rho ≤-0.6 or ≥0.6) with various symptoms (insomnia, dyspnea, cognitive and emotional functioning) during treatment. Associations between routine laboratory parameters albumin, CA19-9, CEA and CRP and HRQoL were overall weaker. None of the investigated proteins were associated with pain.
Conclusions
This is, to our knowledge, the first study exploring associations between serum biomarkers and HRQoL in patients with pancreatic or other periampullary cancer, and some findings merit further validation. The proteoglycan decorin (DCN) is of particular interest as it has been linked to conditions such as Alzheimer’s disease and schizophrenia. Chemotherapy is known to cause persistent cognitive dysfunction with effects on memory and executive function, referred to as “chemo brain”. It would therefore be of great value to identify biomarkers for early detection and management of this debilitating condition.
Clinical trial identification
NCT03724994.
Editorial acknowledgement
Legal entity responsible for the study
Region Skåne.
Funding
This work is supported by peer reviewed grants from the Swedish Research Council (grant number 2015-03598 and 2018-02441), the Swedish Cancer Society (grant number CAN 2018/418 and 21 1596 Pj), the SjöbergFoundation, the Lennart GlansFoundation, BioCARE, the Mrs Berta KampradFoundation, the Ingrid and Sverker PerssonFoundation, the Faculty of Medicine, Lund University, Governmental Funding of Clinical Research (ALF), and Skåne University Hospital Donations and Funds.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1634P - Extensive molecular profiling of KRAS wild-type versus KRAS mutant pancreatic ductal adenocarcinoma on 233 patients
Presenter: Jeanne Lena
Session: Poster session 22
1635P - Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic ductal adenocarcinoma patients
Presenter: Giulia Orsi
Session: Poster session 22
1636P - Circulating tumor DNA (ctDNA) profile in patients (pts) with pancreatic cancer (PC): A multicenter experience and challenges for clinical application
Presenter: Francisco Muñoz i Carrillo
Session: Poster session 22
1637P - Early retention of KRAS mutations in cfDNA is an ominous sign for pancreatic cancer patients during chemotherapy: A prospective cohort study
Presenter: Chien-Jui Huang
Session: Poster session 22
1638P - The prognostic and predictive role of class III β-tubulin and hENT1 expression in patients with advanced pancreatic ductal adenocarcinoma
Presenter: Taha Koray Sahin
Session: Poster session 22
1639P - Feasibility of tumor genomic sequencing on tissue obtained from endoscopic ultrasound in patients with pancreatic cancer
Presenter: Vaia Florou
Session: Poster session 22
1640P - Response monitoring with ctDNA in metastatic pancreatic cancer
Presenter: Jinwoo Ahn
Session: Poster session 22
1642P - Prognostic impact of an immunomorphological signature integrating immune, fibroblastic and tumor markers in a series of 217 resected pancreatic adenocarcinoma patients
Presenter: Franck MONNIEN
Session: Poster session 22
1643P - Clinical outcomes of FOLFIRINOX as front-line therapy in patients with localized pancreatic adenocarcinoma: Asian retrospective study of 781 patients
Presenter: Kyunghye Bang
Session: Poster session 22